Longboard Pharmaceuticals Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Public

  • Employees
  • 33

Employees

  • Share Price
  • $59.98
  • (As of Friday Closing)

Longboard Pharmaceuticals General Information

Description

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Contact Information

Formerly Known As
Arena Neuroscience
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 4275 Executive Square
  • Suite 950
  • La Jolla, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 4275 Executive Square
  • Suite 950
  • La Jolla, CA 92037
  • United States
+1 (858)

Longboard Pharmaceuticals Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Longboard Pharmaceuticals Stock Performance

As of 29-Nov-2024, Longboard Pharmaceuticals’s stock price is $59.98. Its current market cap is $2.34B with 39M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$59.98 $59.96 $3.65 - $60.03 $2.34B 39M 1.72M -$2.25

Longboard Pharmaceuticals Financials Summary

As of 30-Sep-2024, Longboard Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 995,510 88,345 (20,368) (27,945)
Revenue 0 0 0 0
EBITDA (87,599) (56,822) (44,777) (27,860)
Net Income (76,344) (54,422) (43,945) (27,797)
Total Assets 297,005 50,697 70,616 108,952
Total Debt 3,734 475 740 524
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Longboard Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Longboard Pharmaceuticals‘s full profile, request access.

Request a free trial

Longboard Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Longboard Pharmaceuticals‘s full profile, request access.

Request a free trial

Longboard Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative
Drug Discovery
La Jolla, CA
33 As of 2022

New York, NY
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Longboard Pharmaceuticals Competitors (3)

One of Longboard Pharmaceuticals’s 3 competitors is Neurogene, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurogene Formerly VC-backed New York, NY
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA
Cerebral Therapeutics Venture Capital-Backed Aurora, CO
You’re viewing 3 of 3 competitors. Get the full list »

Longboard Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Longboard Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Longboard Pharmaceuticals‘s full profile, request access.

Request a free trial

Longboard Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated February, 16, 2024

21.42 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Commercial Services

Industry

of 428

Rank

Percentile

Business Support Services

Subindustry

of 171

Rank

Percentile

To view Longboard Pharmaceuticals’s complete esg history, request access »

Longboard Pharmaceuticals FAQs

  • When was Longboard Pharmaceuticals founded?

    Longboard Pharmaceuticals was founded in 2020.

  • Where is Longboard Pharmaceuticals headquartered?

    Longboard Pharmaceuticals is headquartered in La Jolla, CA.

  • What is the size of Longboard Pharmaceuticals?

    Longboard Pharmaceuticals has 33 total employees.

  • What industry is Longboard Pharmaceuticals in?

    Longboard Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Longboard Pharmaceuticals a private or public company?

    Longboard Pharmaceuticals is a Public company.

  • What is the current stock price of Longboard Pharmaceuticals?

    As of 29-Nov-2024 the stock price of Longboard Pharmaceuticals is $59.98.

  • What is the current market cap of Longboard Pharmaceuticals?

    The current market capitalization of Longboard Pharmaceuticals is $2.34B.

  • Who are Longboard Pharmaceuticals’s competitors?

    Neurogene, Neurona Therapeutics, and Cerebral Therapeutics are competitors of Longboard Pharmaceuticals.

  • What is Longboard Pharmaceuticals’s annual earnings per share (EPS)?

    Longboard Pharmaceuticals’s EPS for 12 months was -$2.25.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »